Upstream Bio (NASDAQ:UPB) Trading Down 7.3% - Should You Sell?

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) shares traded down 7.3% on Tuesday . The company traded as low as $9.30 and last traded at $9.15. 7,240 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 325,232 shares. The stock had previously closed at $9.87.

Upstream Bio Price Performance

The business has a 50-day moving average of $9.04.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently added to or reduced their stakes in UPB. BNP Paribas Financial Markets acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $25,000. US Bancorp DE acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $28,000. Summit Investment Advisors Inc. acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $30,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $47,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.